ClinicalTrials.gg
CompletedNCT05305664Updated Jul 17, 2026Results posted

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

A Phase 3 interventional study of Pelacarsen (TQJ230) 80 mg s.c. and Corresponding Placebo in Hyperlipoproteinemia(a), sponsored by Novartis Pharmaceuticals. Completed at 13 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Phase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established cardiovascular disease currently undergoing lipoprotein apheresis in Germany on a weekly schedule.

Read the detailed description

Lipoprotein apheresis to date is the only approved therapeutic option for cardiovascular (CV) risk reduction in patients with severely elevated Lp(a) levels in Germany. Lipoprotein apheresis is an expensive, burdensome, and time-consuming procedure. The current study (CTQJ230A12302) investigated if treatment with pelacarsen (TQJ230) 80 mg Q4W vs placebo reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia(a) and established CV disease

02

Conditions studied

  • Hyperlipoproteinemia(a)

Keywords

  • Lipoprotein (a)
  • cardiovascular disease
  • apheresis
  • TQJ230
  • pelacarsen
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 51 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients currently undergoing lipoprotein apheresis for isolated Lp(a) on a weekly schedule in Germany for ≥ 12 months prior to screening with at least 40 sessions within the past 52 weeks prior to randomization
  • Lipoprotein(a) (Lp(a))> 60 mg/dL at screening
  • Spontaneous prior myocardial infarction (MI): ≥ 3 months from screening visit to ≤ 10 years prior to the screening visit, and/or
  • Ischemic stroke: ≥ 3 months from screening visit to ≤ 10 years prior to the screening visit, and/or
  • symptomatic peripheral artery disease (PAD)
  • Clinically significant symptomatic coronary artery disease (PAD)

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension
  • Heart failure (NYHA) class IV
  • History of of any organ system
  • History of hemorrhagic stroke or other major bleeding
  • count \<140,000 per mm3 at screening
  • Active liver disease or hepatic dysfunction
  • Significant kidney disease
  • Pregnant or nursing women
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Pelacarsen (TQJ230)

    Pelacarsen (TQJ230) 80 mg s.c. Q4W

    Drug: Pelacarsen (TQJ230) 80 mg s.c.

  • Placebo comparator
    Placebo

    Placebo to Pelacarsen s.c. Q4W

    Drug: Corresponding Placebo

Interventions

  • Pelacarsen (TQJ230) 80 mg s.c. Q4W

    Also known as: TQJ230

  • DrugCorresponding Placebo

    Placebo to Pelacarsen

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule

    Rate (proportion) of apheresis sessions was calculated as the number of actual lipoprotein apheresis (LA) sessions received, divided by the number of planned LA sessions during the 52-week period, which is 52 for patients who completed all study visits, or pro-rated for those who discontinued early. This rate could range from 0 to 1, with 0 indicating that the patient had skipped all planned LA sessions, and 1 indicating that the patient had received all planned sessions. Multiple imputation for missing Lp(a) data was performed, and missing apheresis data was imputed.

    Time frame: Up to Week 52

Secondary outcomes

  1. Time to Lipoprotein Apheresis Avoidance

    Lipoprotein apheresis avoidance is defined as at least 24 consecutive weeks of no lipoprotein apheresis until end of study.

    Time frame: From randomization up to Week 52

  2. Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 12 to Week 52

    Total lipoprotein apheresis avoidance is defined as no apheresis performed from Week 12 to Week 52.

    Time frame: Week 12 up to Week 52

  3. Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as mg/dL

    Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as particle mass (mg/dL). Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.

    Time frame: Baseline, week 52

  4. Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as Nmol/L

    Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as molar concentration (nmol/L). Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.

    Time frame: Baseline, week 52

Other outcomes

  1. Rate of Lipoprotein Apheresis Sessions From Week 12 to Week 52 and Week 24 to Week 52 Normalized to the Weekly Lipoprotein Apheresis Schedule

    Rate (proportion) of apheresis sessions is calculated using the following formula: the total number of apheresis sessions performed over the double-blinded treatment period/total weeks from Week12 to Week52 or total weeks from Week24 to Week52. Multiple imputation for missing Lp(a) data was performed and missing apheresis data were imputed.

    Time frame: Week 12 to 52, Week 24 to 52

  2. Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 24 to Week 52

    Number of participants with no apheresis performed between week 24 to week 52.

    Time frame: Week 24 to Week 52

  3. Time-averaged Lp(a) Levels Reported as mg/dL

    Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.

    Time frame: Baseline, Week 52

  4. Time-averaged Lp(a) Levels Reported as Nmol/L

    Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.

    Time frame: Baseline, Week 52

  5. Percentage Change in Total Cholesterol, LDL-C, High-density Lipoprotein-Cholesterol (HDL-C), Non-HDL-C, Very-low-density Lipoprotein-Cholesterol (VLDL-C), apoB and Triglycerides (Pre- Lipoprotein Apheresis) From Baseline to Week 52

    Evaluate the change in expanded lipid profile parameters measured in mg/dL

    Time frame: Baseline, Week 52

  6. Change From Baseline to Week 52 in the Physical Health Summary Score for the SF-36 Questionnaire

    The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline, Week 52

  7. Change From Baseline to Week 52 in the Mental Health Summary Score for the SF-36 Questionnaire

    The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline, Week 52

  8. Patient Preference Questionnaire

    Participants were asked for their treatment preference between weekly lipoprotein apheresis or monthly self-injection. The number of participants that prefer each option at baseline and 52 weeks is reported.

    Time frame: Baseline, Week 52

07

Results

Posted Jul 17, 2026

Participant flow

A total of 51 participants were recruited in 13 centers across Germany

Participant flow — Overall Study
MilestonePelacarsen (TQJ230)Placebo
Started2625
Completed2523
Not completed12
Withdrew: Adverse event01
Withdrew: Death01
Withdrew: Physician decision10

Outcome measures

PrimaryRate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule

Rate (proportion) of apheresis sessions was calculated as the number of actual lipoprotein apheresis (LA) sessions received, divided by the number of planned LA sessions during the 52-week period, which is 52 for patients who completed all study visits, or pro-rated for those who discontinued early. This rate could range from 0 to 1, with 0 indicating that the patient had skipped all planned LA sessions, and 1 indicating that the patient had received all planned sessions. Multiple imputation for missing Lp(a) data was performed, and missing apheresis data was imputed.

Time frame:
Up to Week 52
Reported as:
Mean · Apheresis sessions received per week
Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule
Apheresis sessions received per weekPelacarsen (TQJ230)Placebo
Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule0.16 (0.04 to 0.25)0.93 (0.90 to 1.00)
Statistical analysis
  • Pelacarsen (TQJ230) vs Placebo · fractional regression model · p = <0.0001 (one sided) · Odds ratio (or): 0.006 · 95% CI 0.003 to 0.013
SecondaryTime to Lipoprotein Apheresis Avoidance

Lipoprotein apheresis avoidance is defined as at least 24 consecutive weeks of no lipoprotein apheresis until end of study.

Time frame:
From randomization up to Week 52
Reported as:
Median · weeks
Time to Lipoprotein Apheresis Avoidance
weeksPelacarsen (TQJ230)Placebo
Time to Lipoprotein Apheresis Avoidance6.14 (3.14 to 10.14)NA (NA to NA)
Statistical analysis
  • Pelacarsen (TQJ230) vs Placebo · Regression, Cox · p = 0.0014 (one-sided) · Hazard ratio (hr): 88.26 · 95% CI 4.71 to 1653.15
SecondaryNumber of Participants With Total Lipoprotein Apheresis Avoidance From Week 12 to Week 52

Total lipoprotein apheresis avoidance is defined as no apheresis performed from Week 12 to Week 52.

Time frame:
Week 12 up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 12 to Week 52
ParticipantsPelacarsen (TQJ230)Placebo
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 12 to Week 52180
Statistical analysis
  • Pelacarsen (TQJ230) vs Placebo · Regression, Logistic · p = 0.0005 (one-sided) · Odds ratio (or): 163.20 · 95% CI 7.66 to 3477.25
SecondaryChange From Baseline to Week 52 in the Log-transformed Lp(a) Reported as mg/dL

Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as particle mass (mg/dL). Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.

Time frame:
Baseline, week 52
Reported as:
Geometric mean · ratio from baseline
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as mg/dL
ratio from baselinePelacarsen (TQJ230)Placebo
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as mg/dL0.32 (0.26 to 0.39)1.11 (0.89 to 1.38)
Statistical analysis
  • Pelacarsen (TQJ230) vs Placebo · ANCOVA · p = <0.0001 (one sided) · Geometric mean ratio: 0.28 · 95% CI 0.21 to 0.39
SecondaryChange From Baseline to Week 52 in the Log-transformed Lp(a) Reported as Nmol/L

Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as molar concentration (nmol/L). Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.

Time frame:
Baseline, week 52
Reported as:
Geometric mean · ratio from baseline
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as Nmol/L
ratio from baselinePelacarsen (TQJ230)Placebo
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as Nmol/L0.27 (0.21 to 0.34)1.14 (0.89 to 1.45)
Statistical analysis
  • Pelacarsen (TQJ230) vs Placebo · ANCOVA · p = <0.0001 (one sided) · Geometric mean ratio: 0.23 · 95% CI 0.16 to 0.33
Other pre-specifiedRate of Lipoprotein Apheresis Sessions From Week 12 to Week 52 and Week 24 to Week 52 Normalized to the Weekly Lipoprotein Apheresis Schedule

Rate (proportion) of apheresis sessions is calculated using the following formula: the total number of apheresis sessions performed over the double-blinded treatment period/total weeks from Week12 to Week52 or total weeks from Week24 to Week52. Multiple imputation for missing Lp(a) data was performed and missing apheresis data were imputed.

Time frame:
Week 12 to 52, Week 24 to 52
Reported as:
Mean · Apheresis session per week
Rate of Lipoprotein Apheresis Sessions From Week 12 to Week 52 and Week 24 to Week 52 Normalized to the Weekly Lipoprotein Apheresis Schedule
Apheresis session per weekPelacarsen (TQJ230)Placebo
12 to 52 weeks - Imputed data0.11 (0.00 to 0.10)0.93 (0.88 to 1.00)
24 to 52 weeks - Imputed data0.10 (0.00 to 0.07)0.93 (0.96 to 1.00)
Statistical analysis
  • Pelacarsen (TQJ230) vs Placebo · Fractional regression model · p = <0.0001 (one-sided) · Odds ratio (or): 0.003 · 95% CI 0.001 to 0.011
  • Pelacarsen (TQJ230) vs Placebo · Fractional regression model · p = <0.0001 (one sided) · Odds ratio (or): 0.003 · 95% CI 0.001 to 0.015
Other pre-specifiedNumber of Participants With Total Lipoprotein Apheresis Avoidance From Week 24 to Week 52

Number of participants with no apheresis performed between week 24 to week 52.

Time frame:
Week 24 to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 24 to Week 52
ParticipantsPelacarsen (TQJ230)Placebo
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 24 to Week 52190
Statistical analysis
  • Pelacarsen (TQJ230) vs Placebo · Regression, Logistic · p = 0.0004 (one-sided) · Odds ratio (or): 200.93 · 95% CI 9.13 to 4423.17
Other pre-specifiedTime-averaged Lp(a) Levels Reported as mg/dL

Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.

Time frame:
Baseline, Week 52
Reported as:
Mean · mg/dL
Time-averaged Lp(a) Levels Reported as mg/dL
mg/dLPelacarsen (TQJ230)Placebo
Baseline75.4 ± 25.9863.2 ± 15.89
Week 5234.2 ± 32.4173.7 ± 19.78
Other pre-specifiedTime-averaged Lp(a) Levels Reported as Nmol/L

Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.

Time frame:
Baseline, Week 52
Reported as:
Mean · nmol/L
Time-averaged Lp(a) Levels Reported as Nmol/L
nmol/LPelacarsen (TQJ230)Placebo
Baseline159.9 ± 56.67130.1 ± 34.40
Week 5265.6 ± 68.05156.2 ± 44.60
Other pre-specifiedPercentage Change in Total Cholesterol, LDL-C, High-density Lipoprotein-Cholesterol (HDL-C), Non-HDL-C, Very-low-density Lipoprotein-Cholesterol (VLDL-C), apoB and Triglycerides (Pre- Lipoprotein Apheresis) From Baseline to Week 52

Evaluate the change in expanded lipid profile parameters measured in mg/dL

Time frame:
Baseline, Week 52
Reported as:
Mean · percentage change from baseline
Percentage Change in Total Cholesterol, LDL-C, High-density Lipoprotein-Cholesterol (HDL-C), Non-HDL-C, Very-low-density Lipoprotein-Cholesterol (VLDL-C), apoB and Triglycerides (Pre- Lipoprotein Apheresis) From Baseline to Week 52
percentage change from baselinePelacarsen (TQJ230)Placebo
LDL-C3.64 ± 50.4908.85 ± 26.265
Total cholesterol6.23 ± 24.8102.37 ± 17.587
HDL-C16.93 ± 26.059-2.31 ± 13.465
Non-HDL-C1.82 ± 42.2916.97 ± 22.968
VLDL-C2.01 ± 40.2675.31 ± 42.146
Triglycerides31.60 ± 95.8925.08 ± 18.62
Apo-B0.95 ± 36.4886.70 ± 17.652
Other pre-specifiedChange From Baseline to Week 52 in the Physical Health Summary Score for the SF-36 Questionnaire

The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline, Week 52
Reported as:
Mean · scales on a score
Change From Baseline to Week 52 in the Physical Health Summary Score for the SF-36 Questionnaire
scales on a scorePelacarsen (TQJ230)Placebo
Baseline51.2 ± 8.0648.3 ± 9.02
Week 5249.4 ± 9.4450.3 ± 6.76
Change from baseline to Week 52-2.05 ± 6.6530.83 ± 4.554
Statistical analysis
  • Pelacarsen (TQJ230) vs Placebo · ANCOVA · p = 0.0935 (one sided) · Ls mean difference in physical component: -2.44 · 95% CI -6.12 to 1.24with treatment as factor and baseline scores as a covariate
Other pre-specifiedChange From Baseline to Week 52 in the Mental Health Summary Score for the SF-36 Questionnaire

The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline, Week 52
Reported as:
Mean · scales on a score
Change From Baseline to Week 52 in the Mental Health Summary Score for the SF-36 Questionnaire
scales on a scorePelacarsen (TQJ230)Placebo
Baseline53.6 ± 6.7852.6 ± 7.21
Week 5254.8 ± 6.0954.8 ± 6.55
Change from baseline to Week 521.95 ± 6.4363.67 ± 4.589
Statistical analysis
  • Pelacarsen (TQJ230) vs Placebo · ANCOVA · p = 0.2679 · Ls mean difference mental component: -0.98 · 95% CI -4.15 to 2.20with treatment as factor and baseline scores as a covariate.
Other pre-specifiedPatient Preference Questionnaire

Participants were asked for their treatment preference between weekly lipoprotein apheresis or monthly self-injection. The number of participants that prefer each option at baseline and 52 weeks is reported.

Time frame:
Baseline, Week 52
Reported as:
Count of participants · Participants
Patient Preference Questionnaire
ParticipantsPelacarsen (TQJ230)Placebo
Baseline - Weekly apheresis00
Baseline - monthly self-injection2524
Week 52 - Weekly apheresis00
Week 52 - monthly self-injection2019

Adverse events

Collected over From baseline to 16 weeks after last treatment up to 68 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pelacarsen0/26 (0%)7/26 (26.9%)23/26 (88.5%)
Placebo1/25 (4%)6/25 (24%)17/25 (68%)
Total1/51 (2%)13/51 (25.5%)40/51 (78.4%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPelacarsenPlaceboTotal
ArrhythmiaCardiac disorders0/261/251/51
Coronary artery diseaseCardiac disorders0/261/251/51
GastritisGastrointestinal disorders0/261/251/51
Large intestine polypGastrointestinal disorders0/261/251/51
PneumoniaInfections and infestations0/261/251/51
Rib fractureInjury, poisoning and procedural complications0/261/251/51
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/261/251/51
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/261/251/51
SyncopeNervous system disorders1/261/252/51
Myocardial infarctionCardiac disorders1/260/251/51
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPelacarsenPlaceboTotal
Injection site erythemaGeneral disorders and administration site conditions10/260/2510/51
NasopharyngitisInfections and infestations6/269/2515/51
COVID-19Infections and infestations6/265/2511/51
HeadacheNervous system disorders6/260/256/51
Iron deficiencyMetabolism and nutrition disorders2/265/257/51
FatigueGeneral disorders and administration site conditions5/261/256/51
Respiratory tract infectionInfections and infestations5/260/255/51
Injection site pruritusGeneral disorders and administration site conditions4/261/255/51
Back painMusculoskeletal and connective tissue disorders4/262/256/51
Influenza like illnessGeneral disorders and administration site conditions3/260/253/51

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pelacarsen (TQJ230)PlaceboTotal
<=18 years000
Between 18 and 65 years151530
>=65 years111021
Age, Continuous
Age, Continuous(years)Pelacarsen (TQJ230)PlaceboTotal
Mean62.0 ± 8.1061.4 ± 9.3561.7 ± 8.65
Sex: Female, Male
Sex: Female, Male(Participants)Pelacarsen (TQJ230)PlaceboTotal
Female6612
Male201939
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pelacarsen (TQJ230)PlaceboTotal
Race — White262551
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pelacarsen (TQJ230)PlaceboTotal
Ethnicity — Not hispanic or latino262551
Participants with prior clinically significant symptomatic coronary artery disease
Participants with prior clinically significant symptomatic coronary artery disease(Participants)Pelacarsen (TQJ230)PlaceboTotal
Count of participants134
Participants with prior miocardial infarction
Participants with prior miocardial infarction(Participants)Pelacarsen (TQJ230)PlaceboTotal
Count of participants211940
Participants with prior ischemic stroke
Participants with prior ischemic stroke(Participants)Pelacarsen (TQJ230)PlaceboTotal
Count of participants156

2 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • Novartis Investigative Site
    Villingen-Schwenningen, Baden-Wurttemberg 78052, Germany
  • Novartis Investigative Site
    Munich, Bavaria 81377, Germany
  • Novartis Investigative Site
    Würzburg, Bavaria 97080, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60431, Germany
  • Novartis Investigative Site
    Göttingen, Lower Saxony 37075, Germany
  • Novartis Investigative Site
    Düsseldorf, North Rhine-Westphalia 42010, Germany
  • Novartis Investigative Site
    Geilenkirchen, North Rhine-Westphalia 52511, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Cloppenburg, 49661, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
09

References and documents

Publications

  • Parhofer KG, Julius U, Herzog AL, Kruger T, Weinmann-Menke J, Heine GH, Cao H, Schorr J, Ferber P, Wang J, Cristante E, Muller-Edenborn B, Vogt A, Schettler V, Steinhagen-Thiessen E. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. Eur Heart J. 2026 Jul 1;47(25):3284-3294. doi: 10.1093/eurheartj/ehag073. PubMed 41721795 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jan 2025, 29 months.

Results were first posted in Jul 2026, 1 year 5 months after primary completion.

Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's 29 months is below that.

Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2022
First posted
Mar 31, 2022
StartActual
Aug 19, 2022
Primary completionActual
Jan 28, 2025
CompletionActual
Jan 28, 2025
Results first posted
Jul 17, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05305664
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Aug 19, 2022
Primary completion
Jan 28, 2025
Completion
Jan 28, 2025
Results posted
Jul 17, 2026
Last update
Jul 17, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelacarsen

Start the discussion